

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (each, a “**Director**” and collectively, the “**Directors**”) of HighTide Therapeutics, Inc. (the “**Company**”) hereby announces that Mr. LI Li (李鋌) (“**Mr. Li**”) has tendered his resignation as a non-executive Director with effect from February 2, 2024, as he would like to devote more time to his personal engagement.

Mr. Li has confirmed that he has no disagreement with the Board and there are no matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Li for his valuable contribution to the Company during his tenure of office.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping

Executive Director and Chief Executive Officer

Hong Kong, February 2, 2024

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. Jin LI and Mr. HUNG Tak Wai as independent non-executive Directors.